Literature DB >> 19801674

Identification of a new exosite involved in catalytic turnover by the streptokinase-plasmin activator complex during human plasminogen activation.

Rachna Aneja1, Manish Datt, Balwinder Singh, Shekhar Kumar, Girish Sahni.   

Abstract

With the goal of identifying hitherto unknown surface exosites of streptokinase involved in substrate human plasminogen recognition and catalytic turnover, synthetic peptides encompassing the 170 loop (CQFTPLNPDDDFRPGLKDTKLLC) in the beta-domain were tested for selective inhibition of substrate human plasminogen activation by the streptokinase-plasmin activator complex. Although a disulfide-constrained peptide exhibited strong inhibition, a linear peptide with the same sequence, or a disulfide-constrained variant with a single lysine to alanine mutation showed significantly reduced capabilities of inhibition. Alanine-scanning mutagenesis of the 170 loop of the beta-domain of streptokinase was then performed to elucidate its importance in streptokinase-mediated plasminogen activation. Some of the 170 loop mutants showed a remarkable decline in k(cat) without any alteration in apparent substrate affinity (K(m)) as compared with wild-type streptokinase and identified the importance of Lys(180) as well as Pro(177) in the functioning of this loop. Remarkably, these mutants were able to generate amidolytic activity and non-proteolytic activation in "partner" plasminogen as wild-type streptokinase. Moreover, cofactor activities of the 170 loop mutants, pre-complexed with plasmin, against microplasminogen as the substrate showed a similar pattern of decline in k(cat) as that observed in the case of full-length plasminogen, with no concomitant change in K(m). These results strongly suggest that the 170 loop of the beta-domain of streptokinase is important for catalysis by the streptokinase-plasmin(ogen) activator complex, particularly in catalytic processing/turnover of substrate, although it does not seem to contribute significantly toward enzyme-substrate affinity per se.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801674      PMCID: PMC2781679          DOI: 10.1074/jbc.M109.046573

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Crystal structure of streptokinase beta-domain.

Authors:  X Wang; J Tang; B Hunter; X C Zhang
Journal:  FEBS Lett       Date:  1999-10-01       Impact factor: 4.124

2.  Crystal structure of the catalytic domain of human plasmin complexed with streptokinase.

Authors:  X Wang; X Lin; J A Loy; J Tang; X C Zhang
Journal:  Science       Date:  1998-09-11       Impact factor: 47.728

3.  Role of the amino-terminal region of streptokinase in the generation of a fully functional plasminogen activator complex probed with synthetic peptides.

Authors:  D Nihalani; R Kumar; K Rajagopal; G Sahni
Journal:  Protein Sci       Date:  1998-03       Impact factor: 6.725

4.  Mapping of the plasminogen binding site of streptokinase with short synthetic peptides.

Authors:  D Nihalani; G P Raghava; G Sahni
Journal:  Protein Sci       Date:  1997-06       Impact factor: 6.725

5.  Deletion of Ile1 changes the mechanism of streptokinase: evidence for the molecular sexuality hypothesis.

Authors:  S Wang; G L Reed; L Hedstrom
Journal:  Biochemistry       Date:  1999-04-20       Impact factor: 3.162

6.  Streptokinase-plasmin(ogen) activator assays.

Authors:  J T Radek; D J Davidson; F J Castellino
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

7.  Converting tissue-type plasminogen activator into a zymogen.

Authors:  K Tachias; E L Madison
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

8.  Identification of a plasminogen binding region in streptokinase that is necessary for the creation of a functional streptokinase-plasminogen activator complex.

Authors:  G L Reed; L F Lin; B Parhami-Seren; P Kussie
Journal:  Biochemistry       Date:  1995-08-15       Impact factor: 3.162

9.  Extent of N-terminal methionine excision from Escherichia coli proteins is governed by the side-chain length of the penultimate amino acid.

Authors:  P H Hirel; M J Schmitter; P Dessen; G Fayat; S Blanquet
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

10.  Kinetic analysis of covalent hybrid plasminogen activators: effect of CNBr-degraded fibrinogen on kinetic parameters of Glu1-plasminogen activation.

Authors:  P P Lee; R C Wohl; I G Boreisha; K C Robbins
Journal:  Biochemistry       Date:  1988-09-20       Impact factor: 3.162

View more
  5 in total

1.  Identification through combinatorial random and rational mutagenesis of a substrate-interacting exosite in the gamma domain of streptokinase.

Authors:  Suman Yadav; Rachna Aneja; Prakash Kumar; Manish Datt; Sonali Sinha; Girish Sahni
Journal:  J Biol Chem       Date:  2010-12-17       Impact factor: 5.157

2.  Site-specific PEGylation of micro-plasmin for improved thrombolytic therapy through engineering enhanced resistance against serpin mediated inhibition.

Authors:  Navneet Kaur; Prakash Kumar Sinha; Girish Sahni
Journal:  PLoS One       Date:  2019-05-29       Impact factor: 3.240

3.  Contribution of Streptokinase-Domains from Groups G and A (SK2a) Streptococci in Amidolytic/Proteolytic Activities and Fibrin-Dependent Plasminogen activation: A Domain-Exchange Study

Authors:  Maryam Rafipour; Malihe Keramati; Mohammad Mehdi Aslani; Arash Arashkia; Farzin Roohvand
Journal:  Iran Biomed J       Date:  2019-08-28

4.  PEGylation of Truncated Streptokinase Leads to Formulation of a Useful Drug with Ameliorated Attributes.

Authors:  Pooja Sawhney; Keya Katare; Girish Sahni
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

5.  Amino-Terminal Fusion of Epidermal Growth Factor 4,5,6 Domains of Human Thrombomodulin on Streptokinase Confers Anti-Reocclusion Characteristics along with Plasmin-Mediated Clot Specificity.

Authors:  Neeraj Maheshwari; Satish Kantipudi; Anand Maheshwari; Kashika Arora; Neha Kwatra; Girish Sahni
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.